close

Icagen, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered small molecule drugs that modulate ion channel targets. The company's primary drug candidates include ICA-105665 that is in the Phase I multiple ascending dose study in healthy volunteers and epilepsy patients for epilepsy and neuropathic pain; and Senicapoc, which is in the Phase II proof-of-concept clinical trials for the treatment of asthma. It also engages in conducting ongoing drug discovery programs that focus on new therapeutics for pain and inflammatory disorders. Icagen, Inc. has a collaborative research and license agreement with Pfizer Inc. for the discovery, development, manufacture, and commercialization of compounds and products that modulate three specific sodium ion channels as new potential treatments for pain and related disorders. The company was founded in 1992 and is based in Durham, North Carolina.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	5.99
Volume	10254
Volume Avg	108369
52 Week High	8.40
52 Week Low	1.03
PE	N/A
PE (group average)	39
EPS Year	-0.83
EPS change Q/Q	-138.46%
EPS change Q/Q Yr ago	-42.59%
EPS change Q/Q next Q est	-8.82%
EPS change Y/Y	-294.34%
REV change Q/Q	-56.52%
REV change Q/Q Yr ago	-33.33%
EPS next Q est	-0.34
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%